drugset / Trial / NCT01432483
Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
Summary
The purpose of this study is to provide continued therapy with Denileukin diftitox (ONTAK) to patients who are currently on therapy and who have no other suitable treatment options, where therapy is requested by their physician.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | denileukin diftitox | Protein / enzyme biologic | 9 ug/kg | Intravenous |
| Background | denileukin diftitox | Protein / enzyme biologic | 18 ug/kg | Intravenous |